Correction to: Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders (Journal of Neurology, (2024), 271, 7, (3879-3896), 10.1007/s00415-024-12426-w)

In the original version of this article, in the caption of Fig. 1, in the last sentence of the legend for panel A “Eculizumab targets the C5 complement component to block complement-mediated cytotoxicity”, “and ravulizumab” should be added. The sentence should read “Eculizumab and ravulizumab target the C5 complement component to block complement-mediated cytotoxicity”. In the last sentence of the legend for panel B “Satralizumab and ravulizumab inhibit the IL-6 receptor, reducing B cell differentiation into plasma cells and decreasing plasma cell antibody production”, ravulizumab should be changed into tocilizumab. The sentence should read “Satralizumab and tocilizumab inhibit the IL-6 receptor, reducing B cell differentiation into plasma cells and decreasing plasma cell antibody production”. In the keys in Fig. 4 the colours assigned to tocilizumab (red) and ravulizumab (light blue) are switched with respect to those used in the graph (red for ravulizumab and light blue for tocilizumab). Figure 4 should have appeared as shown below. (Figure presented.) Bubble graph showing the percentage of patients who were AQP4-IgG positive and free of relapse in the active treatment and respective placebo arms during the randomized control period of the different RCTs. Size of the bubbles represent the total number of AQP4-IgG positive NMOSD patients evaluated in each arm. Created with biorender.com. See text for further details. Abbreviations: AQP4-IgG aquaporin 4 IgG antibody, NMOSD neuromyelitis optica spectrum disorder.